NCT03118570: A trial that was reported late by Ultragenyx Pharmaceutical Inc
This trial has reported, although it was 438 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03118570 |
|---|---|
| Title | A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 11, 2017 |
| Completion date | Oct. 1, 2019 |
| Required reporting date | Sept. 30, 2020, midnight |
| Actual reporting date | Dec. 13, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 438 |